Navigation Links
Sinovac Reports Unaudited Second Quarter Financial Results
Date:8/14/2014

100.0%

27,504

100.0%Cost of goods sold6,303

24.6%

6,853

24.9%Gross profit19,333

75.4%

20,651

75.1%Total sales for the first half of 2014 were $25.6 million, a decrease of 6.8% from $27.5 million in the same period of 2013. Sales for the first half of 2014 were impacted by decreased sales of the Company's hepatitis A vaccine, Healive, as a result of the challenging environment in the private-pay market.

Gross profit for the first half of 2014 was $19.3 million, a decrease of 6.4% from $20.7 million in the same period of 2013. Gross margin was 75.4% in the first half of 2014, compared to 75.1% in the same period of 2013.

Selling, general and administrative expenses for the first half of 2014 were $16.4 million, compared to $15.9 million for the same period of 2013.

R&D expenses in the first half of 2014 were $5.0 million, compared to $3.9 million in the same period of 2013. These expenses are primarily related to the continued advancement of pipeline vaccine candidates.Net loss attributable to stockholders in the first half of 2014 was $2.2 million or $(0.04) per basic and diluted share, compared to a net loss of $0.7 million, or $(0.01) per basic and diluted share, in the same period of 2013.

As of June 30, 2014, cash and cash equivalents totaled $89.6 million, compared to $107.2 million as of December 31, 2013. Net cash used in operating activities was $11.4 million during the first half of 2014. Net cash used in investing activities was $5.7 million, which was primarily used for payment
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
2. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
5. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
6. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
7. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
8. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
9. MarketResearch.com: New Biotechnology Market Research Reports Added to Kalorama Information Knowledge Center
10. GenVec Reports Second Quarter 2014 Financial Results
11. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 27 PDL BioPharma, Inc. (PDL, ... it has entered into separate privately negotiated exchange agreements under ... the Company,s outstanding 2.00% Convertible Senior Notes due February 15, ... holders of the 2012 Notes will receive $92.0 million in ...
Cached Biology Technology:Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 2Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 3Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 4Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 5Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 6Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 7Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 8The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 2PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 3
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... often spreads silently into more advanced stages before being ... Nanotechnology , biological engineers and medical scientists at the ... a much earlier warning signal. "Early detection can ... test available for lung cancer," said Michael Wang, MD, ...
... September 15, 2011 The Allen Institute for Brain Science ... in the spinal cord that act like neural stem cells, ... treat spinal cord injury and disease. The published collaborative study, ... Allen Institute for Brain Science and The Montreal Neurological Institute ...
... squirrels are getting ready to hibernate they don,t just get ... would make a bodybuilder jealous. And they do it without ... other anabolic steroids usually cause. University of Toronto Scarborough (UTSC) ... and their results could someday have implications for human health. ...
Cached Biology News:MU researchers unveil new method for detecting lung cancer in Nature article 2New class of stem cell-like cells discovered offers possibility for spinal cord repair 2Arctic ground squirrels muscle up to hunker down 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
QPRT Antibody...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
Agarose, Biotechnology grade, 500g...
Biology Products: